The QualityStocks Daily Tuesday, May 14th, 2024

Today's Top 3 Investment Newsletters

Schaeffer's(FFIE) $0.2852 +367.54%

QualityStocks(MTC) $8.9000 +83.51%

MarketClub Analysis(HOLO) $3.2300 +61.50%

The QualityStocks Daily Stock List

MMTec Inc. (MTC)

QualityStocks, StreetInsider, MarketClub Analysis, StockMarketWatch, TradersPro, Stockhouse, FreeRealTime and BUYINS.NET reported earlier on MMTec Inc. (MTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MMTec Inc. (NASDAQ: MTC) is a firm that is engaged in asset management services on various platforms. The firm has its headquarters in Beijing in the People’s Republic of China and was founded in 2015.

The firm provides solutions in securities settlements, market transactions and internet-based technology services to brokerage firms, mutual and hedge funds, proprietary trading groups and registered investment advisors worldwide. MMTec’s operating segments are MM Global and Gujia. The firm generates the majority of its revenue from the Gujia segment, which provides investor relations management and market data services to consumers in China.

MMTec Inc. is mainly involved in offering complete suite trading solutions, which include settlement and trading, distribution, custody and fund creation services, all of which assist financial institutions in boosting their integration into markets abroad. It also allows its consumers to select modular functionalities and white label its trading interface.

The firm’s platforms include the quantitative investment transaction platform, ETN counter business system, institutional and personal integrated account management systems, PC transaction client systems for Web, Android, PC and Apple IOS, personal mobile trading client system and PTN private fund investment management systems, which support requisition management, multi-account management, liquidation, fund valuation, risk management and quantitative trading access.

MMTec Inc. is near the top firms in its industry group, ranking at 74 in the Software Application Industry with its involvement in cryptocurrency moving the company higher up. Companies involved in the “currency of the future” may reap big benefits, particularly because the world is moving further into the digital realm, which will require more use of digital currencies.

MMTec Inc. (MTC), closed Tuesday's trading session at $8.9, up 83.5052%, on 4,221,044 volume. The average volume for the last 3 months is 706,922 and the stock's 52-week low/high is $0.3572/$12.90.

TSS, Inc. (TSSI)

QualityStocks, ProTrader, Monster Alerts, Wall Street Resources, Fortune Stock Alerts, PennyPickAlerts, MarketBeat,, PennyStockScholar, OnPoint Stock Alert, OTCtipReporter, Penny Stock Titans, Buzz Stocks, Penny Pick Finders, PennyStockProphet, StockOnion, Wall Street Mover, Brilliant Penny Stocks, PoliticsAndMyPortfolio, Penny Stock Prodigy,, Profitable Trader Authority, RedChip, Stock Guru, StockEarnings, Top Pros' Top Picks and Planet Penny Stocks reported earlier on TSS, Inc. (TSSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TSS, Inc. is a data center facilities and technology services company listed on the OTC Markets’ OTCQB. It is a trusted single source provider of mission-critical planning, design, system integration, deployment, maintenance and evolution of data centers facilities and information infrastructure. The Company previously went by the name Fortress International Group, Inc. It changed its name to TSS, Inc. in June of 2013. Formed in 2004, TSS has its head office in Round Rock, Texas – with satellite offices in Dulles and Virginia City, as well as Los Altos, California.

The Company specializes in customizable end to end solutions powered by industry experts and unique services. These services include technology consulting, engineering, design, construction, operations, facilities management, technology system installation and integration, and maintenance for traditional and modular data centers.

TSS enables businesses to streamline their IT (Information Technology) infrastructure across their operation with its Enterprise Computing services. Services include pre-deployment verification; rack and stack, modular data centers, field deployments, end of life processing and remarketing.

In addition, TSS provides an array of End-User Computing services, from configuration to remarketing, to fit the requirements of any digital workspace. Services include desktop, laptop, and tablet configuration; peripherals management; order fulfillment; managed deployment; order consolidation; data migration; and application patching among other services offered.

TSS, Inc. (TSSI), closed Tuesday's trading session at $1.4, up 50.5376%, on 170,052 volume. The average volume for the last 3 months is 6.391M and the stock's 52-week low/high is $0.24/$1.49.

SINTX Technologies (SINT)

QualityStocks, StockMarketWatch, TradersPro, BUYINS.NET, MarketClub Analysis, Broad Street, StocksEarning, InvestorPlace, Trades Of The Day, The Stock Dork, The Online Investor, StreetInsider, MarketBeat, InvestorIntel and INO Market Report reported earlier on SINTX Technologies (SINT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SINTX Technologies Inc. (NASDAQ: SINT) (FRA: 111N) is an original equipment manufacturing ceramics firm that is engaged in researching, developing, manufacturing and commercializing silicon nitride for non-medical and medical applications in South America, Europe and the U.S.

The firm has its headquarters in Salt Lake City, Utah and was founded 1996 by Ashok C. Khandkar and Aaron A. Hofmann. Prior to its name change in October 2018, the firm was known as Amedica Corporation. It operates in the materials industry, under the chemicals sub-industry and serves consumers from different parts of the globe.

The company is party to a collaboration agreement with Oxford Performance Materials Inc. which entails the development of a silicon nitride composite that will be based off of the solution casting technology by OXPEKK SC. It generates product revenue mainly from the sale and manufacture of spinal fusion products utilized in treating spine disorders.

The enterprise provides ceramic-based solutions for various anti-pathogenic, industrial and medical applications. Its pipeline comprises of silicon nitride coating, silicon nitrite powder, porous and solid silicon nitride products. Silicon nitride is compatible and bioactive across all imaging modalities, which provides patients and surgeons with a preferable alternative to the commonly used materials. Additionally, the enterprise is involved in the development of corrosion-and wear-resistant implant components for knee and hip joint replacements and markets spinal fusion products.

After entering into an agreement with 02TODAY in February 2021, the firm recently sold its first shipment of anti-pathogenic silicon nitride powder which is used in the manufacture of mask filters and face masks. With the pandemic raging on, this collaboration is bound to bring in more revenue as well as attract investors into Sintx.

SINTX Technologies (SINT), closed Tuesday's trading session at $0.055, up 41.7526%, on 157,355,686 volume. The average volume for the last 3 months is 38,634 and the stock's 52-week low/high is $0.0206/$1.82.

Comstock Holding Companies (CHCI)

Wall Street Resources, OTCPicks, StockMarketWatch, TradersPro, MarketBeat, MarketClub Analysis, CoolPennyStocks, StreetInsider, StockEgg, TraderPower, PennyTrader Publisher,, PennyStocks24, BUYINS.NET, Penny Invest, Forbes, Greenbackers, QualityStocks, HotOTC, CRWEWallStreet, MicrocapVoice, InvestorPlace, Eagle Financial Publications, DrStockPick, CRWEPicks, CRWEFinance, BestOtc, FeedBlitz, Stock Rich, Wise Alerts, Wall Street Wolves, The Street, The Online Investor, Street Insider, StockRockandRoll, StockHotTips, PennyStockLocks, Stock Stars, Penny Stock 101, SmallCapReview, ProfitableTrading,, WiseAlerts, PennyToBuck, AllPennyStocks, PennyOmega and Stock Traders Chat reported earlier on Comstock Holding Companies (CHCI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Comstock Holding Companies Inc. (NASDAQ: CHCI) (FRA: CHO1) is a construction services and real estate development firm that is engaged in the development, operation and management of properties in the state of Washington.

The firm has its headquarters in Reston, Virginia and was incorporated in 1985 by Christopher Clemente. Prior to its name change in June 2012, the firm was called Comstock Homebuilding Companies Inc. It operates in the consumer discretionary sector, under the home construction sub-industry and mainly serves the Washington DC marketplace.

The enterprise, which also provides asset management services, operates through the real estate, homebuilding and multi-family and asset management services segments. The asset management services segment is engaged in the provision of services to real estate businesses and assets that include retail stores, leased lands, commercial garages, office buildings, hotels and apartments while the former segment is engaged in the provision of real estate services in the design and environmental-based services, brokerage services, capital markets and strategic corporate planning areas. The enterprise’s environmental services team provides remediation services, environmental studies, engineering and consulting services, in addition to offering site specific solutions for various projects that may have an effect on the environment from site-specific remediation and assessments to environmental due diligence. On the other hand, its homebuilding and multi-family segment is focused on property development with an intent to sell them as condominiums or fee-simple properties, with a focus on projects that range between 70 to 200 units.

The firm recently released its financial results for the first quarter of 2021 which show an increase in total revenue and operating as well as net income. Its CEO noted that the firm is well positioned to build on its accomplishments and is currently on course to grow, which may bring in more investors into the company.

Comstock Holding Companies (CHCI), closed Tuesday's trading session at $8.54, up 16.5075%, on 40,347 volume. The average volume for the last 3 months is 26,710 and the stock's 52-week low/high is $3.47/$8.56.

Kingstone Companies (KINS)

QualityStocks, StreetInsider, MarketBeat, Zacks, Trading Concepts, The Street Report, StocksEarning, Short Term Wealth, Investors Alley and InvestorPlace reported earlier on Kingstone Companies (KINS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kingstone Companies Inc. (NASDAQ: KINS) is a holding firm that provides property and casualty insurance policies to individuals and small businesses.

The firm has its headquarters in Kingston, New York and was incorporated in 1886. Prior to its name change in July 2009, the firm was known as DCAP Group Inc. It operates as part of the insurance-property and casualty industry, under the financial services sector. The firm serves consumers in the United States.

The company primarily operates through its Kingstone Insurance Company subsidiary, which is a licensed property and casualty insurance firm that offers its insurance products in New Jersey, Connecticut, New York, Massachusetts and Rhode Island. It underwrites its business utilizing industry claims databases, insurance scoring reports, physical inspection of risks and other individual risk underwriting tools. The company writes homeowners and dwelling fire business in coastal markets.

The enterprise provides personal line of insurance products, including homeowners and dwelling fire multi-peril, renters, cooperative/condominiums, and personal umbrella policies. It also offers canine legal liability policies; for-hire vehicle physical damage only policies for livery and car service vehicles and taxicabs; as well as reinsurance products. It sells its products through retail and wholesale agents and brokers.

The firm recently announced its latest financial results, with its CEO noting that they were well-positioned to better manage their risks on an efficient platform. It remains committed to driving profitability and enhanced value for its shareholders, which will in turn bolster the firm’s overall growth.

Kingstone Companies (KINS), closed Tuesday's trading session at $4.6, up 14.7132%, on 73,111 volume. The average volume for the last 3 months is 10.687M and the stock's 52-week low/high is $1.045/$4.8193.

Liberty TripAdvisor (LTRPA)

InvestorPlace, StockEarnings, QualityStocks, BUYINS.NET, Trades Of The Day, The Street, MarketClub Analysis, Zacks, StockMarketWatch, Money Wealth Matters and MarketBeat reported earlier on Liberty TripAdvisor (LTRPA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty TripAdvisor Holdings Inc. (NASDAQ: LTRPA) (FRA: LT0A) is a diversified holding firm that operates as an online travel firm that connects travel partners with travelers.

The firm has its headquarters in Englewood, Colorado and was incorporated in 2014, on August 27th. It has thirty-five companies in its corporate family and serves consumers around the globe, with a focus on the United States and the United Kingdom. The firm operates through its BuySeasons and TripAdvisor subsidiaries.

The company operates through the Experiences and Dining, and the Hotels, Media and Platform segments. The former segment is engaged in the provision of information and services for consumers to experience, book and research activities. On the other hand, the latter segment comprises of technical infrastructure, company-related brand advertising expenses and other costs that support the company’s platform.

The enterprise operates an online restaurant booking platform dubbed TheFork; and a website that provides book, research and experience attractions and activities in travel destinations known as the Viator. Its travel platform offers tools for price comparison, content and online reservation and associated services for restaurants, accommodations and destinations. The enterprise also operates and owns a portfolio of travel media brands and businesses which provide trip-taking and travel-planning resources in the travel industry. This is in addition to offering subscription-based, display-based and click-based advertising services.

The company has a presence in the United Kingdom and the United States as well as other countries. Expanding into new territories, as the firm is currently focused on doing, would not only boost the company’s growth but also bring in more investments into the company.

Liberty TripAdvisor (LTRPA), closed Tuesday's trading session at $0.53, up 13.2721%, on 1,210,918 volume. The average volume for the last 3 months is 328,306 and the stock's 52-week low/high is $0.151/$1.95.

Delta Apparel (DLA)

SmarTrend Newsletters, Zacks,, StreetInsider, The Street, StockMarketWatch, InvestorPlace, CRWEFinance, CRWEPicks, CRWEWallStreet, Daily Market Beat, Daily Profit, DrStockPick, FNNO Newsletters, MarketBeat, BestOtc, PennyToBuck, QualityStocks, StockEarnings, StockHotTips, Trader Prep, Trading Concepts and PennyOmega reported earlier on Delta Apparel (DLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Delta Apparel Inc. (NYSE American: DLA) (FRA: DA7) is a global apparel design, marketing, manufacturing and sourcing firm for activewear and lifestyle apparel products.

The firm has its headquarters in Duluth, Georgia and was incorporated in 1903. It operates as part of the apparel manufacturing industry, under the consumer cyclical sector. The firm serves consumers around the world, with a focus on those in the United States, Mexico, El Salvador, and Honduras.

The enterprise operates through the Delta Group and Salt Life Group segments. It provides performance shirts that keep athletes dry under the Delta Dri line brand; on-demand digitally printed apparel products under the DTG2Go brand; ringspun garments; silhouettes and fleece products; Delta Soft apparel products; and headwear, polos, outerwear, bags, and other accessories under the Soffe brand, as well as heritage, mid- and heavier-weight tee shirts under the Delta Pro Weight and Magnum Weight brand names. The enterprise also distributes its products to different audiences, including specialty and resort shops, sporting goods and outdoor retailers, department stores, farm and fleet stores, and mid-tier retailers, as well as through website. In addition to this, it provides sunglasses, swimwear, board shorts, bags, and accessories under the Salt Life brand through specialty stores, surf shops, outdoor retailers, and department stores, as well as through its ecommerce site.

The company, which recently released its latest financial and operational results, remains focused on looking for areas to generate efficiencies and further streamline operations while also evaluating strategic options with the best interest of its shareholders in mind.

Delta Apparel (DLA), closed Tuesday's trading session at $1.6563, up 0.9939024%, on 31,382 volume. The average volume for the last 3 months is 12.499M and the stock's 52-week low/high is $1.61/$11.4949.

Scorpius Holdings Inc. (SCPX)

We reported earlier on Scorpius Holdings Inc. (SCPX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scorpius (NYSE American: SCPX), an integrated contract development and manufacturing organization (“CDMO”), has announced the pricing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit is being offered at a public offering price of $0.10 (inclusive of the pre-funded warrant exercise price) and consists of one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof) and a common warrant to purchase one share of common stock. The common warrants will have an exercise price of $0.12 per share and will be immediately exercisable upon issuance for a period of five years. The gross proceeds to Scorpius are expected to be approximately $6,000,000, from which it intends to use the net proceeds to fund working capital, general corporate purposes, and the repayment of a $750,000 non-convertible promissory note, plus accrued and unpaid interest. In addition, the company granted the underwriters a 45-day option to purchase up to an additional 9,000,000 shares of common stock (and/or pre-funded warrants) and/or up to an additional 9,000,000 common warrants solely to cover over-allotments, if any. Subject to customary conditions, the offering is expected to close on May 16, 2024. ThinkEquity is acting as sole book-running manager for the offering.

To view the full press release, visit

About Scorpius Holdings Inc.

Scorpius is an integrated large molecule contract development and manufacturing organization (“CDMO”) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, visit

Scorpius Holdings Inc. (SCPX), closed Tuesday's trading session at $0.0768, off by 57.686%, on 19,330,804 volume. The average volume for the last 3 months is 6.639M and the stock's 52-week low/high is $0.0699/$0.885.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, PsychedelicNewsWire, Prism MarketView, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A survey conducted by YouGov has found that a majority of U.S. citizens have used marijuana before, and most of them revealed that the experience was a positive one. This survey also discovered that 20% of Americans have also tried “magic mushrooms” (psilocybin mushrooms), and an even bigger proportion of these users reported that the experience was a positive one.

This poll comes at a time when the Biden administration is taking steps to reschedule marijuana while many states are also looking to reform their laws around psychedelics. The poll provides a deep dive into what Americans think of these efforts to tweak the different policies and laws on these substances.

The poll asked respondents about four substances: cannabis, LSD, psilocybin and MDMA. Marijuana led with a wide margin (57%) when respondents were asked to indicate the substances they had ever used, psilocybin came in second at 20%, LSD followed at 16%, and MDMA rounded off the set at 11%.

The respondents who admitted using any of those substances also reported that their experience was a positive one. The survey noted that 65% of psilocybin mushroom users categorized their experience of the substance as positive, 57% said using marijuana was a positive experience, 56% said the same for MDMA while 55% had a positive experience using LSD. Psilocybin stands out as having the largest percentage of its users describing the experience as positive.

It is noteworthy that only 8% of those who admitted using psilocybin described it as a negative experience while 20% said using LSD, marijuana or MDMA was a negative experience.

On matters of legalization, cannabis stood out by attracting majority support with 60% saying its use should be made legal. Only 27% wanted psilocybin legalized, 16% supported MDMA legalization, while 15% said LSD should be made legal.

When the poll narrowed down the legalization question to those who had ever used each of those substances, only LSD didn’t attract majority support for its legalization. Cannabis had 78% of those who had used it saying it should be made legal, 63% of those who had used psilocybin supported its legalization, and 55% of those who had used MDMA said it should be made legal. LSD users were divided on the subject, with 43% voicing their opposition to its legalization while 38% were in support of its legalization.

This survey was conducted April 25–28, 2024. The total number of respondents was 1,134, and only adults were polled. A 4% margin of error was factored into the findings.

The public sentiment toward many psychedelics is likely to spur on startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) to ramp up their R&D drug-development efforts since the public is already positive toward several psychedelic compounds.

Seelos Therapeutics Inc. (SEEL), closed Tuesday's trading session at $0.2424, off by 11.8866%, on 1,293,207 volume. The average volume for the last 3 months is 98.515M and the stock's 52-week low/high is $0.24/$49.80.

TerrAscend Corp. (TSNDF)

QualityStocks, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Germany is progressing with the next stage of cannabis legalization by initiating a pilot program for commercial sales using an administrative process instead of waiting for legislators to pass a separate measure as initially anticipated. It has long been expected that lawmakers would introduce and approve additional sales bills to complete the second phase of legalization. However, the government is opting for a rulemaking approach, potentially expediting the implementation process.

Cannabis legalization was set in motion under a measure led by Germany’s Ministry of Health, which went into force in April 2024. This allows adults to use and grow marijuana and join clubs for access to the plant, with cooperative launches expected in July. Nonetheless, there is currently no established commercial sales road map.

According to a report from Tagesspiegel Background, the existing law provides regulatory flexibility to build upon the original reform. Germany’s Ministry of Agriculture has the authority to create regulations for a commercial pilot initiative, enabling adults to purchase marijuana in specific areas without requiring further legislative action.

However, this approach also raises the possibility of easier reversal by a future government. Nevertheless, in the short-term, expediting the sales process is possible. According to reports, representatives from the Agricultural Ministry have sent out a letter asking for comments by May 10, 2024, on possible rules on retail sales under a pilot initiative.

Karl Lauterbach, Germany’s health minister, who has been leading the government’s marijuana legalization efforts, mentioned to Bundestag members last year that the commercial sales program is under consideration. With legalization already in place, there is growing pressure to accelerate this process.

Previously, the Bundesrat representing different states attempted to block the legalization proposal enacted last September, but this effort failed. Bundesrat members later worked with Lauterbach and other government officials to find a compromise.

The first legalization framework was accepted by Germany’s cabinet in late 2022, but to uphold its international responsibilities, the government sought approval from the European Union. Hearings were held in 2022 to provide legislation that would remove the prohibition.

In November 2023, government representatives from various countries, including the United States, convened in Germany to discuss international cannabis policy as the host country pursued legalization.

A delegation of German legislators visited the United States in 2022, touring marijuana businesses in California to inform Germany’s approach to legalization. The visit followed a groundbreaking meeting between Netherlands, Germany, Malta and Luxembourg officials to discuss plans and obstacles related to recreational cannabis legalization.

The coalition government leaders revealed some details of their agreement to legalize cannabis in 2021 and declared that they had come to an agreement to eliminate prohibition.

Meanwhile, the drug control arm of the United Nations recently restated its stance that legalizing cannabis for nonscientific or nonmedical purposes violates international treaties. However, it acknowledged Germany’s government for scaling back its marijuana plans before the upcoming vote.

This expedited way to get adult-use cannabis sales underway is likely to be applauded by the wider marijuana industry, including major companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), because as it would facilitate access to recreational marijuana for Germans who are interested in consuming the substance.

TerrAscend Corp. (TSNDF), closed Tuesday's trading session at $1.78, up 4.0936%, on 461,792 volume. The average volume for the last 3 months is 510,632 and the stock's 52-week low/high is $1.29/$2.45.

Momo Inc. (MOMO)

StocksEarning, MarketClub Analysis, InvestorPlace, Schaeffer's, StockEarnings, QualityStocks, Marketbeat, Market Intelligence Center Alert, The Street, Zacks, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Street Report,, The Online Investor, BUYINS.NET, Market Report, FreeRealTime, Trading Concepts, Louis Navellier, TradersPro, Wealth Insider Alert, StreetAuthority Daily, TopStockAnalysts, Money Morning, Investopedia, DividendStocks, Daily Wealth, ChineseWire, PennyDoctor, TipRanks, Greenbackers, StockMarketWatch, StocksImpossible, Street Insider, OTCBB Journal, Early Bird, First Penny Picks, ChartAdvisor, Barchart, CrashTrade, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A rise in romance scams with human-trafficking ties has led to increased calls for Congressional action on the risks posed by dating apps. While romance scammers on dating apps typically coerce users into giving them money, there has been an uptick in dating app scams with human-sex-trafficking implications.

A recent series of CBS News reports, titled “Anything for Love,” shined a light on romance scams on dating applications and websites that pull their victims into horrific human-sex-trafficking rings. For example, 57-year-old, Illinois-based widow Laura Kowal fell victim to such a scam and was duped into giving her money to the scammers and laundering money taken from other victims. She later went missing and was ultimately found dead.

The Federal Bureau of Investigation (FBI) believes that dating apps are a hotbed of criminal activity and even published a notice in March 2020 stating that vulnerable individuals are being targeted through dating apps. According to the FBI’s alert, human sex traffickers “exploit” these platforms for the recruitment and advertisement of sex. This warning came after the release of several investigative news reports, which discovered that some of the most popular dating apps in the world don’t have robust measures to prevent criminals and sexual predators from exploiting other users.

As a result, sexual predators and even human traffickers can easily create accounts on dating apps and use those accounts to target vulnerable users. Since dating apps have become one of the most common ways to meet romantic partners, millions of users now face the risk of romance scams and even human trafficking. The latter is one of the most pressing worldwide issues because it leads to immense suffering and provides funding for international criminal activity and terrorism.

Experts estimate that some 27.6 million people globally are being trafficked in criminal rings that generate up to $150 billion annually. However, trafficking rings have to consistently bring in new victims to maintain their profits, meaning they are always on the hunt for new people to exploit and ultimately traffic. With tens of millions of users and weak security measures, dating apps have made it easier for criminals to zero in on people with a higher likelihood of falling for romance scams.

Dating apps such as Match Group are aware that registered sex offenders and minors have accounts on the platform but have taken little effort to remedy the issue, a 2019 ProPublica report said. Following the report, Match Group received a letter from two house representatives asking it to outline the steps it would take to prevent human trafficking and sexual violence as well as vet sexual offenders. Raja Krishnamoorthi, a house subcommittee chair at the time, also sent letters to the four most popular dating apps demanding information on how they keep minors off their platforms.

The threats that are raising concern on dating apps in the United States are likely to be present in the Chinese online dating space where companies such as Momo Inc. (NASDAQ: MOMO) are vested. The industry needs to come up with innovative ways to monitor users on those platforms with an aim of cracking the whip on wrong actors.

Momo Inc. (MOMO), closed Tuesday's trading session at $6.05, off by 1.7857%, on 1,185,291 volume. The average volume for the last 3 months is 5.632M and the stock's 52-week low/high is $5.30/$11.12.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, Trades Of The Day, MarketBeat, StocksEarning, Daily Trade Alert, Kiplinger Today, StockEarnings, The Online Investor, QualityStocks, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, Stock Up Featured, StreetAuthority Daily, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, Wall Street Grand, SeriousTraders,, StockMarketWatch, INO Market Report, Money Morning, Early Bird, Profit Trends, StocksToBuyNow, Trading For Keeps, Jim Cramer, CNBC Breaking News, Inside Trading, Louis Navellier, Cannabis Financial Network News, MarketClub, BUYINS.NET, Outsider Club, Timothy Sykes, Cabot Wealth, Beat The Street, VectorVest, AllPennyStocks, Trading Concepts, TradersPro, Wealth Daily, Insider Wealth Advice, Profit Confidential, InvestmentHouse, Tim Bohen, Investors Alley, TheTradingReport, Technology Profits Daily, Stock Gumshoe, Rick Saddler, Money and Markets, Raging Bull All Access, 24/7 Trader and Investment U reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lawmakers in Illinois are calling for increased oversight over the state’s largely unregulated hemp derivatives market. This market ballooned in the years after the 2018 Farm Bill legalized industrial hemp and hemp extracts across the United States under state and tribal programs.

In the wake of this legislation, many businesses took advantage of legal loopholes to process and sell hemp derivatives such as cannabidiol (“CBD”), and delta-8 THC. While these derivatives technically aren’t illegal under federal law, there are few if any federal or state regulations governing their production and sale. As a result, Illinois and other states with hemp programs have seen a surge in hemp products that claim to do everything from alleviating stress and depression to treating physical illnesses.

On top of making misleading claims of the products’ medical efficacy, many players in the hemp derivatives segment don’t exercise high-level quality control, resulting in low-quality products that often contain harmful contaminants. Policymakers are now considering creating a regulatory framework for the state’s hemp sector to rein in the hemp derivatives grey market through two measures: Senate Bill 3790 and House Bill 5306.

Introduced by Representative La Shawn Ford, House Bill 5306 would require that entrepreneurs in the hemp extracts space register their businesses before they can begin selling hemp extract products. Ford notes that few companies come out and ask for lawmakers to regulate and tax their industries, preferring instead for the government to “get out of the way.” However, his measure would ensure the government’s involvement in hemp by mandating hemp businesses to buy a state license and pay taxes on both retail and wholesale sales.

Under Ford’s measure, businesses would have to pay $500 for a state operating license on top of a 10% retail sales tax and a 10% wholesale sales tax, without a limit on the number of hemp businesses allowed to operate in the state. These three taxes would cumulatively earn Illinois $1.5 billion in tax revenue through the next four years. The proposed hemp measure would also institute the testing of hemp products, limit extract dosages and make it illegal to sell hemp products that are designed to resemble nonhemp candies and snacks.

According to Ford, hemp businesses that sell high-dose or unsafe products or sell to underage individuals (under 21 years) could lose their licenses. Although hemp products typically have minimal to low levels of delta-9 THC and are not intoxicating, the measure would limit the sale of hemp-derived products to Illinois residents 21 years of age and older.

The call to license businesses selling hemp products is a fair one because in markets where companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) operate, they acquire licenses that need to be renewed periodically; many feel that hemp businesses should follow similar regulations.

Canopy Growth Corp. (CGC), closed Tuesday's trading session at $9.7, up 3.4115%, on 14,066,142 volume. The average volume for the last 3 months is 26,211 and the stock's 52-week low/high is $2.755/$19.20.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an electric vehicle ("EV") manufacturer, has received a $100 million financing commitment from a family office; the company has also sold up to an additional $50 million of senior secured convertible notes to family offices and high net worth investors. According to the announcement, this $150 million capital infusion allows Mullen and Bollinger to operate and expand domestic and international commercial sales efforts as well as meet its capital needs over the next 13 months. This news comes on the heels of several advancements announced by the company, including California Air Resource Board ("CARB") HVIP approval on the Mullen THREE, Class 3 EV truck, providing up to $45,000 cash voucher at time of vehicle purchase; the addition of Pritchard EV and National Auto Fleet Group to the company's expanding commercial dealer network; and receiving Foreign Trade Zone Status approval for its Tunica, Mississippi, commercial vehicle manufacturing center.

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $6.13, up 6.0554%, on 9,645,264 volume. The average volume for the last 3 months is 122,273 and the stock's 52-week low/high is $2.3565/$1341.00.

Recent News


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

The meshing of Web3 and artificial intelligence (AI) is happening at an ever-increasing pace, and blockchain tech is proving to be a major influence in the way AI shapes up for the future. The costs of innovation in AI are high, with the computational needs and large data sets needed to train models being out of reach for the majority. As a result, there is a risk that innovations in AI and the financial rewards from such innovation could be a preserve of a few individuals and entities that can mobilize the needed resources to drive innovation. Proprietary data, such as in the finance and healthcare sectors, can also be safely leveraged in the development of AI solutions without risking the privacy and security of that data by using federated learning or homomorphic encryption, among other Web3 technologies. Businesses then earn rewards for availing their proprietary data during the AI development process. Blockchain technology is bound to play an increasing role in furthering and deepening AI's reach in different industries and sectors. Entities that are already leveraging AI, such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), could see themselves incorporating even more advanced technologies as Web3 matures.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.33, up 8.5714%, on 186,609 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1341.00/$.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, including legalized cannabis, released its financial results for Q1 2024, the period ended March 31; the company also noted recent business highlights. According to the report, financial highlights include revenues totaling $837,052 for the quarter ended March 31, 2024, compared to $688,024 million revenues for the same quarter 2023, representing an increase of 22%; net income of $96,473, or $0.01 per fully diluted share, as compared to a net loss of $309,648, or ($0.03) per fully diluted share, for the same quarter in 2023, representing a 131% increase; income from operations totaled $128,909 for the quarter; cash provided by operating activities reached $207,218; operating expenses reaching $708,143; and reported cash on hand of $1.52 million as of March 31, 2024. Business highlights for the quarter include Zoned Properties board of directors approving a stock repurchase program; the acquisition of a prime dispensary location in Chicago, marking an entry into one of the largest urban markets for legalized cannabis; an agreement to acquire property leased to Sunday Goods after receiving cannabis approvals for a new retail dispensary in Arizona; and listing cultivation property in Chino Valley, Arizona, for sale at a purchase price of $16 million. "Our team continues to execute despite a difficult operating climate in the cannabis industry, achieving very impressive financial and operational results," said Zoned Properties CEO Bryan McLaren in the press release. The transition to a direct-to-consumer property investment model was demonstrated by our first-quarter results, which saw a revenue increase of 22%, positive net income and significant operating cash flow growth, evidencing what we believe is Zoned Properties' firm trajectory of value generation and sustainable growth."

To view the full press release, visit

Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.


The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Tuesday's trading session at $0.68, up 15.2542%, on 11,790 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News


The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRsafe recently secured two new contracts: a hardware/software agreement with a Southern California-based behavioral health provider operating three facilities, and a reseller agreement with a new San Antonio, Texas-based channel partner

The behavioral health provider purchased and installed a SOBRcheck(TM) device in each of its three facilities to facilitate point-of-care alcohol screening

SOBRcheck(TM) has been shown to streamline operations and reduce expenses, delivering results instantaneously compared to 45 seconds per person in cases where breathalyzer tests were administered

SOBRsafe's new channel partner purchased an initial three SOBRcheck(TM) devices and two SOBRsure(TM) wearable wristbands and plans to place an additional order for both devices

So far in 2024, SOBRsafe has secured 18 new accounts, compared to three accounts booked in all of 2023

SOBRsafe (NASDAQ: SOBR), a provider of next-generation, transdermal alcohol-detection solutions, has inked two new hardware/software agreements, bringing its total new contracts to date for this year to 20. The company has entered agreements with Lighthouse Recovery Resources and Mountain House Recovery. Lighthouse Recovery Resources provides individuals and families with resources and support to achieve lasting recovery, including interventions, sober companions and care management. Lighthouse purchased an initial 10 SOBRsure wristbands. Mountain House Recovery provides a post-treatment platform designed for young men in early recovery to forge lasting friendships and embark on a transformative journey in sobriety. Mountain House is integrating SOBRcheck point-of-care screening in its residential facility to replace breathalyzers. To view the full press release, visit

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.


The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.


With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.


SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.


SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.


Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Tuesday's trading session at $0.2339, up 1.5632%, on 43,669 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004/$2.15.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX (OTC: GEMZ), a leading provider of exquisite gemstone jewelry, has announced a partnership with Latin Energy Partners Inc. ("LEP") that both companies are calling a "landmark move" in the pursuit of oil exploration and development. The strategic collaboration is designed to support the company's expansion of its business mode. According to the announcement, the agreement outlines terms for the two companies to jointly drill four test wells in a promising geological formation in a Latin America country. The agreement is based on promising preliminary explorations in two target basins that have shown extensive sedimentary deposits conducive to successful oil and gas systems. The companies noted that estimates suggest these basins may hold more than one billion barrels each of recoverable oil, creating an extraordinary opportunity for both GEMXX and LEP to establish a footprint in the global oil and gas market. An emerging leader and an independent E&P company, LEP is involved in exploring significant hydrocarbon reserves in Latin America, one of the world's underexplored hydrocarbon regions. "We are excited for this strategic partnership with Latin Energy Partners, which perfectly aligns with our long-term goals," said GEMXX CEO Richard Clowater in the press release. "We are eager to combine our expertise to fully harness the potential of these promising basins."

To view the full press release, visit

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.


GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Tuesday's trading session at $0.02825, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0172/$0.20.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada ("NRC")

Specific molecular characteristics of the glucagon-peptide 1 ("GLP-1") drug, semaglutide, processed with Lexaria's patented DehydraTECH(TM) technology, will be evaluated

Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control

Lexaria's management is confident that this partnership will complement the company's animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada ("NRC") that will pursue an applied research program to evaluate specific molecular characteristics of the company's patented DehydraTECH(TM) technology processed with glucagon-peptide 1 ("GLP-1") drug, semaglutide, related to its mode of action and performance (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $3.08, off by 3.1447%, on 101,852 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$6.85.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is reporting its financial results for Q1 2024, the period ended March 31, 2024; the company also shared business updates. Highlights of the report include securing a new series production award for its near-rage lidar with a global original equipment manufacturer ("OEM") covering a multiyear period; signing an engineering services contract with partner Koito for approximately $10 million in fees to support execution and product development for the new OEM series production award during Q2 2024; final submission to a top 10 global automotive OEM for an RFQ for long-range lidar; and first submission for an RFQ from a top 3 global automotive OEM for both long-range and near-range lidar. In addition, the company achieved B sample for the Cepton Ultra, its next generation of high-performance, long-range lidar with the smallest form factor in the industry to date and fully integrated MagnoSteer(TM) into Ultra B samples while also launching StudioViz(TM), its proprietary end-to-end lidar simulation platform. Financial numbers include Q1 2024 total revenue of $1.9 million, consisting of $1.1 million product revenue and $0.8 million development revenue, a 31% increase compared to $1.5 million in the same period of 2023; Q1 2024 GAAP net loss of $6.8 million, or $(0.43) per share, basic and diluted with Q1 2024 Non-GAAP net loss coming in at $8.3 million, or $(0.52) per share, basic and diluted; and Adjusted EBITDA for the quarter coming in at $(8.9) million. The company noted it projects full-year 2024 revenue to be between $15 to $25 million with full-year operating expenses expected to be below $50 million. "We started fiscal year 2024 with strong results in our commercial activities, securing a new series production award along with our tier 1 partner, Koito, from a global OEM for our near-range lidar," said Cepton cofounder and CEO Jun Pei in the press release. "We believe we have positioned ourselves as a leader in industrializing lidar for the automotive market."

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Tuesday's trading session at $2.8899, off by 4.3111%, on 34,978 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.38/$8.90.

Recent News

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company's strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through the third quarter of fiscal year 2024; the company's subsidiary, 1st Detect, accepting orders for the TRACER 1000 Narcotics Trace Detector ("NTD"); the TRACER 1000 being listed in the U.S. General Services Administration ("GSA") IT Schedule 70, meaning it can be purchased by the U.S. federal government, one of the largest buyers of goods and services in the world; the formation of a wholly owned subsidiary Pro-Control Inc., which offers the proprietary Pro-Control Maximum Value Processing and the PRO-CONTROL-1000(TM) mass spectrometer, which is designed to test, measure and increase potency, purity and weight yields in the chemical manufacturing space; and First Detect exhibiting TRACER 1000 NTD and ETD at the International Security Conference and Exposition in Las Vegas, Nevada. "We believe mass spectrometry continues to be the best technology for the detection of explosives," said Astrotech chair, CEO and chief technology officer Thomas B. Pickens III in the press release. "We are continually expanding the product line for new applications and market channels. The introduction of the TRACER 1000 NTD, a narcotics detection instrument, is expected to extend our product into more markets including military, law enforcement and security. Also, having the 1st Detect TRACER 1000 product added to the GSA list will create even more traction for our technology in the U.S. by making it very easy for government entities to purchase our product without the lengthy budget approval needed for most procurement events. We are expanding the sales department and ramping up sales and marketing efforts in the fourth quarter, which should help maintain the momentum built in fiscal year 2024 into fiscal year 2025."

To view the full press release, visit

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.


Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Tuesday's trading session at $9.0412, off by 1.4046%, on 1,985 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will participate in three investor conferences in May. Clene will participate in one-on-one meetings at the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. See the announcement for more information, including dates and locations of the events.

To view the full press release, visit

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $0.3841, off by 1.7144%, on 373,935 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$1.09.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and business results for the third quarter of 2024, the period that ended March 31, 2024. Business highlights included the announcement of preclinical data supporting both the company's INM-901 and INM-089 programs; the continued development of its ALZ program, with long-term behavioral and mechanism of action/receptor interaction studies underway; and the announcement of Dr. David G. Morgan, a leader in neurodegenerative disease, to the company's scientific advisory board. The report also noted that BayMedica is operating as a profitable business unit with revenues totaling $3.3 million for the reported period. Notable financial numbers for the company included net loss of $5.7 million for the quarter ended March 31, 2024; R&D and patents expenses totaling $2.6 million; and cash, cash equivalents and short-term investments coming in at $7.6 million. "The third quarter of fiscal year 2024 was another positive quarter for the company as we continue to make exciting progress in our pharmaceutical pipeline and deliver steady growth in our commercial business," said InMed Pharmaceuticals president and CEO Eric. A. Adams in the press release. "Last month we announced important updates in our two preclinical programs in the treatment of Alzheimer's disease (‘ALZ') and dry Age-Related Macular Degeneration (‘AMD'). Both programs utilize proprietary small molecule drug candidates activating both the CB1/CB2 receptors as well as other disease-relevant receptors. We are highly encouraged by the positive findings, and we are committed to further advancing our research in these two highly underserved indications. Revenues from the BayMedica commercial business remain consistent with the previous quarter, and BayMedica operated as a profitable commercial business unit in the current quarter. We remain optimistic for the sector as more brands start to incorporate rare cannabinoids into their product portfolios."

To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $0.267, off by 4.6084%, on 67,507 volume. The average volume for the last 3 months is 8.876M and the stock's 52-week low/high is $0.227503/$2.08.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked leverages innovative cutting-edge technology and connectivity to make healthcare more efficient for patients and doctors

The company's HealthLynked Network, a comprehensive and sophisticated cloud-based healthcare platform, connects patients, healthcare providers, and medical facilities, providing centralized information access and communication

Through its sophisticated platform, HealthLynked is changing how patients and medical professionals can, for example, interact with telehealth and telemedicine services

The network facilitates real-time interactions between healthcare providers and patients, greatly improving the efficient delivery of healthcare information and services remotely through a user-facing app, securely transmitting needed patient data on demand

HealthLynked (OTCQB: HLYK) offers cutting-edge technology and connectivity to provide more efficient, accessible, and personalized healthcare, through centralized and integrated information management and access. Among other things, HealthLynked greatly improves the use and effectiveness of remote patient care, such as telemedicine, telehealth, remote monitoring, and direct-to-consumer lab testing.

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Tuesday's trading session at $0.05629, off by 4.2687%, on 18,425 volume. The average volume for the last 3 months is 16,381 and the stock's 52-week low/high is $0.033/$0.0999.

Recent News

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

Significant drought conditions in Mexico with months to go before the fall rainy season have led to concerns one of the world's most populous cities may soon run entirely out of water, with residents currently struggling to make the most of a limited supply

Innovative green tech engineering services company Energy and Water Development Corp. has entered an MOU with some of the city's residents to create first-of-its-kind Off-Grid Atmosphere Water Generation Plant that will extract moisture from the air to ease the crisis

The facility is expected to generate about 3.2 million liters of water annually, with a later phase planned to produce millions more liters of water than the original plant

EAWD is headquartered in Florida and has operations in Germany, where it is also developing solar-powered Off-Grid electric vehicle ("EV") Charging Stations

Energy and Water Development Corp. (OTCQB: EAWD), a leading water and energy solutions provider, was featured in the latest episode of The Harvest Podcast, a series highlighting thought leaders, experts and breakthrough companies making disruptive and impactful contributions to society through groundbreaking initiatives. The company's CEO Irma Velazquez, MSc joined the program to provide an introduction to EAWD and discuss its core values and mission. "Energy and Water Development Corp. is a leading engineering company focused on innovation relating to the generation of sustainable water and energy supply. Leveraging our intellectual property surrounding the configuration of our systems, we put together state-of-the-art technologies that enable the provision of water and energy in any kind of situations in any part of the world," Velazquez said. "When discussing water supply, the challenges stemming from geopolitics and infrastructure really engage you to offer a sustainable solution. The principles of EAWD drive us to find the best and most sustainable solutions, and that requires a lot of investment, research and understanding. Our main objective is to be an evolving company that works with innovations in technology to meet new demands and circumstances presented by climate change."

To view the full press release, visit

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.


In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Tuesday's trading session at $0.0452, off by 16.9118%, on 785,033 volume. The average volume for the last 3 months is 85,857 and the stock's 52-week low/high is $0.0159/$0.12.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.